Previous 10 | Next 10 |
home / stock / biov:cc / biov:cc news
--News Direct-- BioVaxys CEO James Passin joins Natalie Stoberman from the Proactive newsroom to discuss the company's acquisition of TAETSoftware, a Vancouver-based clinical studies management company engaged in the development and commercialization of the Trial Adverse Events Tracker (TAET)...
VANCOUVER, BC / ACCESSWIRE / March 16, 2023 / The Power Play by The Market Herald has announced the release of new interviews with Spey Resources, Melkior Resources and BioVaxys Technology discussing their latest news. The Power Play by The Market Herald provides investors with a quick snapshot...
BIOVAXYS ACQUIRES CLINICAL STUDY MANAGEMENT COMPANY AND COMPLETES PRIVATE PLACEMENT PR Newswire VANCOUVER, BC , March 16, 2023 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") today announced that it h...
VANCOUVER, BC / ACCESSWIRE / December 20, 2022 / The Power Play by The Market Herald has announced the release of new interviews with ApartmentLove, Sirios Resources, Aton Resources, Mountain Boy Minerals and BioVaxys Technology discussing their latest news. The Power Play by The Market Herald ...
BioVaxys and Procare Health Execute US Distribution Agreement for Papilocare Gel and Oral Immunocaps Canada NewsWire VANCOUVER , British Colombia and BARCELONA, Spain , Dec. 19, 2022 /CNW/ - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ...
BioVaxys Co-Founder, President and Chief Operating Officer Kenneth Kovan to Present at MedInvest Oncology Investor Conference Canada NewsWire VANCOUVER, BC , Dec. 5, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxy...
Palm Beach, FL – December 1, 2022 – FinancialNewsMedia.com News Commentary – The global ovarian cancer market is projected to continue to grow through the coming several years. The formation of mutational cells or tissues in female reproductive organs called ovari...
BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine Canada NewsWire VANCOUVER, BC , Dec. 1, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announ...
BIOVAXYS CLOSES FIRST TRANCHE OF NON-BROKERED PRIVATE PLACEMENT Canada NewsWire VANCOUVER, BC , Nov. 28, 2022 /CNW/ -- BioVaxys Technology Corp. ( CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) ( "BioVaxys" or the "Company") announces that it has closed ...
BioVaxys Sarbecovirus Vaccine Interim Data Excellent Emerging Safety & Tolerability Profile with BVX-1021 BioVaxys Sarbecovirus Vaccine Interim Data Excellent Emerging Safety & Tolerability Profile with BVX-1021 Canada NewsWire VANCOUVER, BC , Nov...
News, Short Squeeze, Breakout and More Instantly...
Biovaxys Technology Corp. Company Name:
BIOV:CC Stock Symbol:
CNQC Market:
Biovaxys Technology Corp. Website:
BioVaxys Technology Corp. Announces Failure to File Cease Trade Order PR Newswire VANCOUVER, BC , May 16, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the " Company ") announces that the Ontario Securities Commission (...
Toronto, Ontario--(Newsfile Corp. - Le 16 mai/May 2024) - Effective immediately, BioVaxys Technology Corp. is suspended pursuant to CSE Policy 3. The suspension is considered a Regulatory Halt as defined in National Instrument 23-101 Trading Rules. A cease trade order has been issued by the Ontar...
BioVaxys Technology Corp. Closes SECOND Tranche of Private Placement Canada NewsWire // THIS PRESS RELEASE IS NOT INTENDED FOR RELEASE OR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC , May 10, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: B...